Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-12.73 Insider Own2.60% Shs Outstand21.22M Perf Week11.87%
Market Cap5.45B Forward P/E- EPS next Y-6.05 Insider Trans-31.69% Shs Float14.22M Perf Month11.72%
Income-256.70M PEG- EPS next Q-1.10 Inst Own60.20% Short Float7.15% Perf Quarter12.09%
Sales1.70M P/S3204.59 EPS this Y48.90% Inst Trans-1.35% Short Ratio2.13 Perf Half Y-2.02%
Book/sh13.83 P/B18.56 EPS next Y54.00% ROA-134.70% Target Price473.43 Perf Year373.93%
Cash/sh14.10 P/C18.21 EPS next 5Y-4.07% ROE-331.50% 52W Range46.81 - 497.00 Perf YTD276.00%
Dividend- P/FCF- EPS past 5Y0.00% ROI-47.90% 52W High-48.34% Beta-
Dividend %- Quick Ratio25.80 Sales past 5Y- Gross Margin- 52W Low448.45% ATR13.64
Employees50 Current Ratio25.80 Sales Q/Q0.00% Oper. Margin- RSI (14)60.19 Volatility4.94% 7.18%
OptionableYes Debt/Eq0.00 EPS Q/Q291.10% Profit Margin- Rel Volume0.51 Prev Close250.33
ShortableYes LT Debt/Eq0.00 EarningsNov 12 AMC Payout- Avg Volume476.57K Price256.73
Recom1.90 SMA2014.28% SMA501.20% SMA200-9.18% Volume243,800 Change2.56%
15-Aug-14Initiated FBR Capital Underperform $172
12-Aug-14Reiterated RBC Capital Mkts Outperform $425 → $500
01-Jul-14Initiated RBC Capital Mkts Outperform $425
15-May-14Initiated Summer Street Research Buy $650
08-May-14Reiterated Oppenheimer Outperform $525 → $499
18-Mar-14Reiterated Needham Buy $320 → $500
14-Mar-14Reiterated Oppenheimer Outperform $360 → $525
10-Jan-14Reiterated Oppenheimer Outperform $94 → $360
10-Jan-14Reiterated Needham Buy $55 → $320
01-Oct-13Reiterated Oppenheimer Outperform $64 → $94
13-Aug-13Reiterated Needham Buy $40 → $55
11-Jul-13Reiterated Oppenheimer Outperform $60 → $64
16-Jan-13Reiterated Wedbush Outperform $25 → $46
04-Jan-13Reiterated Needham Buy $24 → $40
05-Nov-12Initiated Needham Buy $24
31-Oct-14 06:01AM  Intercept to Report Third Quarter 2014 Results on November 7 and Present at Upcoming Conferences GlobeNewswire
23-Oct-14 04:04PM  Here's where to put your money to work, pros say at CNBC
02:04PM  Stock pickers shopping list CNBC
08-Oct-14 09:06AM  What We're Trading Yahoo Finance Blogs
06:30AM  Intercept Announces Data to be Presented at the 2014 AASLD Annual Meeting GlobeNewswire
12-Sep-14 06:55AM  Intercept Pharmaceuticals Recognizes International PBC Day GlobeNewswire
02-Sep-14 07:00AM  Get that shopping list ready to buy on the dip at CNBC
29-Aug-14 11:53AM  4 Biotechs That Might Be Bought Soon at Investor's Business Daily
28-Aug-14 01:02PM  [video] 3 Russell outperformers at CNBC
11:45AM  Insider Trading Alert - ACHC, ARO And ICPT Traded By Insiders at TheStreet
27-Aug-14 08:31AM  The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals Zacks
26-Aug-14 02:29PM  Biotech Stocks: Time to Worry at Barrons.com
10:07AM  3 Biotechs Surging Following InterMune Takeover Zacks
08:05AM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
25-Aug-14 05:00PM  [video] $8.3 billion biotech deal at CNBC
03:24PM  Biotech Bounce Gets More Fuel From InterMune Deal at Forbes
11:40AM  InterMune Stock Spikes On Rare Big Biotech Buyout at Investor's Business Daily
19-Aug-14 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials EDGAR Online Financials
15-Aug-14 02:40PM  Intercept Pharmaceuticals: Curb Your Enthusiasm? at Barrons.com
09:41AM  [video] MannKind Snares Sanofi, Intercept Soars & Southwest's Mexico Move at TheStreet
07:21AM  Coverage initiated on Intercept Pharma by FBR Capital Briefing.com
13-Aug-14 05:44PM  Roses in the Market Yahoo Finance Blogs +11.24%
02:05PM  Should Gilead Sciences (GILD) Be in Your Portfolio? Zacks
09:40AM  Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus Zacks
08:11AM  Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% Zacks
12-Aug-14 05:41PM  [video] Stock Pops & Drops: ICPT, TSL, NUAN, RAX at CNBC +16.59%
04:56PM  Roses in the Market... Yahoo Finance Blogs
04:56PM  [video] Stocks Close Down on Light Volume, Pump Prices Expected to Fall at TheStreet
04:06PM  U.S. stocks end lower; Dow turns negative for the year at MarketWatch
03:56PM  [$$] Intercept Releases Positive Data on Liver Drug at The Wall Street Journal
02:44PM  Stock Market Today: Russian Sanctions and Oil in Focus 8/12/14 Zacks
02:32PM  US STOCKS-Wall St falls modestly with Ukraine in focus Reuters
02:10PM  Intercept Pharma (ICPT) Shares Soar on Liver Disease Drug News Zacks
01:03PM  Intercept surges on liver treatment trial at Financial Times
12:24PM  US STOCKS-Wall St dips with Ukraine in focus Reuters
11:34AM  Kate Spade tumbling, JPMorgan sheds unit, Intercept Pharma on fire Yahoo Finance
11:00AM  Intercept Pharmaceuticals: Home Run at Barrons.com
10:59AM  Intercept Rises After Data Shows Liver Disease Drug Works at Bloomberg
10:53AM  Stocks Stake Out Thin Gains; Intercept, Insys, Autohome Gain at Investor's Business Daily
10:48AM  Intercept Pharma Soars On Liver-Disease Drug Data at Investor's Business Daily
10:39AM  Jim Cramer's Mad Dash: The Fed Is Overlooking Biotech Growth at TheStreet
10:31AM  US STOCKS-Wall St flat amid Ukraine uncertainty Reuters
10:27AM  Intercept Pharma Flies Again After Positive Trial For Liver Disease Drug at Forbes
10:12AM  Intercept Soars, and That's Good for Fidelity Investors at Barrons.com
10:04AM  [video] Intercept and Chiquita Shares Soar Despite Lower Market Open at TheStreet
09:32AM  Biotech Stock Surges 45% After Good News On Liver Disease Treatment Business Insider
09:28AM  [video] Cramer's Mad Dash: Intercept soars at CNBC
09:07AM  Stock Futures Hem And Haw; Intercept Pharmaceuticals Soars at Investor's Business Daily
09:05AM  Why Intercept Pharmaceuticals (ICPT) Stock Is Spiking In Pre-Market Trading Today at TheStreet
09:04AM  Caesars big loss; Intercept Pharma soars on positive drug data; Exact Sciences jumps Hot Stock Minute
08:58AM  Ahead of the Bell: Intercept Pharma shares soar AP
08:49AM  [video] Cramer's stocks to watch: Intercept & Exact Sciences at CNBC
08:37AM  Top Analyst Upgrades and Downgrades: AECOM, Intercept, Kinder Morgan, Rackspace, SunEdison, Disney and More at 24/7 Wall St.
07:57AM  Germany feels pressure from Ukraine crisis; Chiquita, Fyffes deal in jeopardy; Higher salary or higher 401(k) match? Hot Stock Minute
06:00AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
11-Aug-14 10:20PM  Intercept Pharma Soars On Positive Liver Drug Data at Investor's Business Daily
07:14PM  [$$] Intercept Releases Positive Data on Liver Drug at The Wall Street Journal
07:08PM  Intercept's liver drug found effective; shares soar Reuters
05:29PM  Intercept Pharma Shares Higher on Positive Fatty Liver Drug Data at TheStreet
05:25PM  Biotech Company Intercept Explodes After Reporting Good News On Liver Disease Treatments Business Insider
05:16PM  Intercept Pharmaceutical's Shares Soar On Earnings Benzinga
04:15PM  Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update GlobeNewswire
04:10PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q2 2014 Intercept Pharmaceuticals Inc Earnings Release - After Market Close CCBN
07-Aug-14 08:20AM  4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher at 24/7 Wall St.
04-Aug-14 05:00PM  Intercept to Host Second Quarter 2014 Update on August 11 and Present at Upcoming Investor Conference GlobeNewswire
28-Jul-14 08:55AM  5 Huge Biotech Catalysts Right Around the Corner for Top Stocks at 24/7 Wall St.
24-Jul-14 10:00AM  Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic Accesswire
23-Jul-14 03:31PM  Puma Biotechnology: Another Jackpot For Investors at Forbes
11:45AM  Puma Pumps up Biotech ETFs ETF Trends
22-Jul-14 05:01PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events EDGAR Online
15-Jul-14 01:40PM  [video] Next global epidemic? at CNBC
08:06AM  This liver disease could rival hepatitis C at CNBC
14-Jul-14 11:51AM  Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation Benzinga
11:47AM  Intercept Pharmaceuticals: 'Good Risk/Reward,' Deutsche Bank Says at Barrons.com
08-Jul-14 08:01AM  Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment at Seeking Alpha -6.11%
03-Jul-14 12:42PM  Could Galectin Therapeutics Stock Be Your Next Home Run? at Motley Fool
01-Jul-14 11:29AM  Biotech: Buy the Trial, Sell the Approval? at Barrons.com
29-Jun-14 01:36PM  5 of Last Week's Biggest Losers at Motley Fool
09:00AM  3 Stocks Crushed by the Market This Week at Motley Fool
27-Jun-14 05:00PM  Are Investors Wrong About Raptor Pharmaceuticals? at Motley Fool
26-Jun-14 07:12PM  Intercept Pharmaceuticals' Drop Proves How Impatient Investors Are at Motley Fool -5.61%
12:18PM  Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following FLINT Data Delay Benzinga
09:40AM  Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs Accesswire
09:03AM  Intercept thesis unchanged with pushed out data, says Summer Street at theflyonthewall.com
25-Jun-14 05:37PM  [video] Stock Pops & Drops: DDD, AGN, ICPT, ZU at CNBC -7.30%
10:50AM  Intercept says FLINT data 'unlikely' to come in July at theflyonthewall.com
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VEITINGER KLAUS R DRDirectorOct 10Option Exercise21.503918,4072,557Oct 15 09:00 PM
VEITINGER KLAUS R DRDirectorOct 10Sale223.6539187,4472,166Oct 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 02Sale233.97832194,66414,855Oct 03 09:00 PM
Pruzanski MarkCEO & PresidentOct 01Option Exercise8.6710,00086,667489,909Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Option Exercise31.901,00031,90017,107Oct 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Option Exercise10.404,00041,60019,875Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Sale231.174,188968,13015,687Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Sale233.121,000233,11916,107Oct 03 09:01 PM
Pruzanski MarkCEO & PresidentOct 01Sale228.8210,0002,288,187479,909Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Option Exercise10.404,00041,60018,253Sep 17 09:04 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Sale281.194,0001,124,75114,253Sep 17 09:04 PM
VEITINGER KLAUS R DRDirectorSep 10Option Exercise21.503918,4072,557Sep 12 09:00 PM
VEITINGER KLAUS R DRDirectorSep 10Sale280.50391109,6762,166Sep 12 09:00 PM
Pruzanski MarkCEO & PresidentSep 02Option Exercise8.6710,00086,667485,042Sep 04 09:11 PM
Pruzanski MarkCEO & PresidentSep 02Sale286.4910,0002,864,883475,042Sep 04 09:11 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Option Exercise8.6710,00086,66724,253Aug 29 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Sale293.9310,0002,939,28614,253Aug 29 09:00 PM
SILVERSTEIN JONATHANDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:06 PM
ORBIMED ADVISORS LLCDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:05 PM
ORBIMED ADVISORS LLCDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:05 PM
WILLIAMS NICOLEDirectorAug 25Sale295.082,433717,9191,465Aug 27 09:00 PM
SILVERSTEIN JONATHANDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:06 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Option Exercise10.404,00041,60019,027Aug 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Sale291.494,7741,391,56814,253Aug 15 09:00 PM
SILVERSTEIN JONATHANDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:13 PM
ORBIMED ADVISORS LLCDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:07 PM
Adorini LucianoChief Scientific OfficerAug 12Option Exercise8.6711,03895,66319,151Aug 15 09:00 PM
Regan Daniel PaulChief Commercial OfficerAug 12Option Exercise37.698,124306,1949,534Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 12Option Exercise21.503166,7942,482Aug 15 09:00 PM
Regan Daniel PaulChief Commercial OfficerAug 12Sale325.708,1242,645,9631,410Aug 15 09:00 PM
Adorini LucianoChief Scientific OfficerAug 12Sale321.6211,0383,550,0788,113Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 12Sale345.62316109,2162,166Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 11Option Exercise21.503918,4072,557Aug 12 09:00 PM
Fundaro PaoloDirectorAug 11Sale239.4932477,5958,803Aug 12 09:03 PM
VEITINGER KLAUS R DRDirectorAug 11Sale238.72555132,4882,166Aug 12 09:00 PM
Pruzanski MarkCEO & PresidentAug 01Option Exercise8.6710,00086,667485,042Aug 06 09:00 PM
Pruzanski MarkCEO & PresidentAug 01Sale226.7210,0002,267,198475,042Aug 06 09:00 PM
VEITINGER KLAUS R DRDirectorJul 10Option Exercise21.503918,4072,171Jul 11 09:00 PM
VEITINGER KLAUS R DRDirectorJul 10Sale219.1539185,6881,780Jul 11 09:00 PM
TALLARIGO LORENZODirectorJul 07Option Exercise9.822,00019,6452,000Jul 09 09:00 PM
TALLARIGO LORENZODirectorJul 07Sale243.062,000486,1100Jul 09 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Option Exercise37.691381,411Jul 08 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Sale250.0012501,410Jul 08 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale247.65849210,25715,027Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Option Exercise8.6710,00086,667485,042Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise10.404,00041,60020,063Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Sale250.6110,0002,506,121475,042Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale244.144,1871,022,19515,876Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJun 02Option Exercise8.6710,00086,667480,174Jun 04 09:00 PM
Pruzanski MarkCEO & PresidentJun 02Sale230.6010,0002,305,993470,174Jun 04 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Option Exercise10.404,00041,60019,183May 19 09:00 PM
Fundaro PaoloDirectorMay 15Option Exercise9.826,92267,9908,577May 19 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Sale276.034,7431,309,20014,440May 19 09:00 PM
TALLARIGO LORENZODirectorMay 09Sale232.0036785,1440May 09 09:01 PM
Fundaro PaoloDirectorMay 09Sale232.0032575,4001,655May 09 09:03 PM
VEITINGER KLAUS R DRDirectorMay 09Sale230.9516237,4141,780May 09 09:02 PM
Adorini LucianoChief Scientific OfficerMay 07Option Exercise10.402,00020,8009,464May 09 09:00 PM
VEITINGER KLAUS R DRDirectorMay 07Sale254.36665169,1501,617May 09 09:02 PM
TALLARIGO LORENZODirectorMay 07Sale259.761,640426,0080May 09 09:01 PM
Adorini LucianoChief Scientific OfficerMay 07Sale259.442,000518,8757,464May 09 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Option Exercise8.6710,00086,667480,174May 02 09:02 PM
Pruzanski MarkCEO & PresidentMay 01Sale263.1710,0002,631,661470,174May 02 09:02 PM
Pruzanski MarkCEO & PresidentApr 16Option Exercise8.6710,00086,667480,174Apr 17 09:00 PM
Pruzanski MarkCEO & PresidentApr 16Sale242.2210,0002,422,166470,174Apr 17 09:00 PM
Pruzanski MarkCEO & PresidentApr 15Option Exercise6.1730,309186,926470,174Apr 17 09:00 PM
Micheli Francesco10% OwnerApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:03 PM
Genextra S.p.A.10% OwnerApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:02 PM
TALLARIGO LORENZODirectorApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:01 PM
ORBIMED ADVISORS LLCDirectorApr 09Sale320.0081,30526,017,6001,654,603Apr 11 05:27 PM
TALLARIGO LORENZODirectorApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:01 PM
SILVERSTEIN JONATHANDirectorApr 09Sale320.0081,30526,017,6001,653,629Apr 11 09:00 PM
Genextra S.p.A.10% OwnerApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:02 PM
Micheli Francesco10% OwnerApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:03 PM
Adorini LucianoChief Scientific OfficerApr 07Option Exercise10.402,00020,8009,041Apr 09 09:00 PM
Adorini LucianoChief Scientific OfficerApr 07Sale283.902,000567,8007,041Apr 09 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentApr 02Sale321.95879282,99713,679Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Option Exercise10.404,32644,99119,072Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Sale333.764,5141,506,58814,558Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMar 17Option Exercise10.408,91792,73817,580Mar 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 17Sale437.494,4561,949,45013,124Mar 19 09:00 PM
Adorini LucianoChief Scientific OfficerMar 07Option Exercise10.402,00020,8008,392Mar 11 09:00 PM
Adorini LucianoChief Scientific OfficerMar 07Sale421.312,000842,6206,392Mar 11 09:00 PM
Regan Daniel PaulChief Commercial OfficerMar 05Option Exercise37.6920,000753,80020,000Mar 07 09:00 PM
Regan Daniel PaulChief Commercial OfficerMar 05Sale434.6920,0008,693,8210Mar 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 14Option Exercise10.404,32745,00112,990Feb 18 09:46 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 14Sale367.115,7722,118,9477,218Feb 18 09:46 PM
Fundaro PaoloDirectorFeb 14Sale367.51324119,0731,655Feb 14 09:00 PM
Fundaro PaoloDirectorFeb 12Option Exercise8.676,92259,9918,901Feb 14 09:00 PM
Fundaro PaoloDirectorFeb 12Sale375.626,9222,600,0291,979Feb 14 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 10Sale377.7216261,1902,282Feb 11 09:02 PM
TALLARIGO LORENZODirectorFeb 10Sale354.52368130,4631,640Feb 11 09:02 PM
Adorini LucianoChief Scientific OfficerFeb 07Option Exercise10.402,00020,8008,392Feb 11 09:00 PM
Adorini LucianoChief Scientific OfficerFeb 07Sale305.152,000610,3006,392Feb 11 09:00 PM
Pruzanski MarkPresident and CEOJan 16Option Exercise8.6710,00086,667440,298Jan 17 09:00 PM
AKKARAJU SRINIVASDirectorJan 16Option Exercise21.502,50053,7505,193Jan 17 09:01 PM
AKKARAJU SRINIVASDirectorJan 16Sale267.943,250870,8051,943Jan 17 09:01 PM
Pruzanski MarkPresident and CEOJan 16Sale273.6810,0002,736,767430,298Jan 17 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 15Option Exercise31.905,625179,43816,333Jan 17 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 15Sale259.185,6251,457,91510,708Jan 17 09:01 PM
Pruzanski MarkPresident and CEODec 30Option Exercise2.8921,50362,120438,138Jan 17 09:00 PM